Fernando L. Riccillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernando L. Riccillo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Kevin I. Martínez
Department of Citology, Histology and Embriology, School of Medical Sciences, National University of La Plata, La Plata, Argentina; National Scientific and Technical Research Council (CONICET), Argentina
2 shared publications Marcela N. García
Department of Citology, Histology and Embriology, School of Medical Sciences, National University of La Plata, La Plata, Argentina
2 shared publicationsEdgardo D. Carosella
Atomic Energy and Alternative Energies Agency (CEA), Hematology and Immunology Research Division, Saint-Louis Hospital, Paris, France; U976 HIPI Unit, University of Paris, Paris, France
1 shared publication- Edgardo D. Carosella
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
1 shared publication Fernando J. Sepúlveda
Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Concepción, Concepción, Chile; Exercise and Rehabilitation, Sciences Institute School of Speech Therapy of Rehabilitation Sciences, Universidad Andres Bello, Santiago, 7591538, Chile
1 shared publication- Fernando J. Sepúlveda1 shared publication
Latest Publications
- 5 June 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (8) , 111768
Cannabidiol modulates classical and non-classical HLA expression in human choriocarcinoma cell line
- 5 June 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (8) , 111768
Cannabidiol modulates classical and non-classical HLA expression in human choriocarcinoma cell line
- Open Access
CANNABIDIOL MODULATES CLASSICAL AND NON-CLASSICAL HLA EXPRESSION IN HUMAN CHORIOCARCINOMA CELL LINE
Cannabidiol (CBD) modulates diverse signaling pathways with potential relevance to tumor immune escape, however its impact on the regulation of classical and non-classical HLA class I molecules remains incompletely understood. Here, we examined the mechanisms by which CBD regulates HLA expression in JEG-3 choriocarcinoma cells, focusing on cannabinoid-related receptors and intracellular Ca²⁺ signaling. CBD increased the expression of classical HLA class I genes—most notably HLA-C—while reducing HLA-G levels, a non-classical HLA class I molecule that acts as a local immunosuppressor. Receptor profiling revealed constitutive expression of CB1 and CB2, whereas GPR55 and PPARγ expression became detectable only after CBD exposure. Functional inhibition assays showed that HLA-G downregulation was selectively attenuated by CB1 blockade, with no meaningful contribution from CB2 or GPR55. In contrast, CBD-induced HLA-C upregulation required GPR55 and CB2 activity, while being unaffected by CB1 inhibition, indicating distinct receptor pathways for classical and non-classical HLA regulation. Calcium chelation using BAPTA further demonstrated that HLA-G modulation is highly sensitive to intracellular Ca²⁺ reduction, whereas classical HLA expression required higher BAPTA concentrations to be affected. Altogether, these findings identify CBD as a dual immunomodulatory agent capable of enhancing tumor immune visibility while limiting immunotolerant HLA-G expression through receptor-specific and Ca²⁺-dependent mechanisms.
Open AccessCANNABIDIOL MODULATES CLASSICAL AND NON-CLASSICAL HLA EXPRESSION IN HUMAN CHORIOCARCINOMA CELL LINE
Cannabidiol (CBD) modulates diverse signaling pathways with potential relevance to tumor immune escape, however its impact on the regulation of classical and non-classical HLA class I molecules remains incompletely understood. Here, we examined the mechanisms by which CBD regulates HLA expression in JEG-3 choriocarcinoma cells, focusing on cannabinoid-related receptors and intracellular Ca²⁺ signaling. CBD increased the expression of classical HLA class I genes—most notably HLA-C—while reducing HLA-G levels, a non-classical HLA class I molecule that acts as a local immunosuppressor. Receptor profiling revealed constitutive expression of CB1 and CB2, whereas GPR55 and PPARγ expression became detectable only after CBD exposure. Functional inhibition assays showed that HLA-G downregulation was selectively attenuated by CB1 blockade, with no meaningful contribution from CB2 or GPR55. In contrast, CBD-induced HLA-C upregulation required GPR55 and CB2 activity, while being unaffected by CB1 inhibition, indicating distinct receptor pathways for classical and non-classical HLA regulation. Calcium chelation using BAPTA further demonstrated that HLA-G modulation is highly sensitive to intracellular Ca²⁺ reduction, whereas classical HLA expression required higher BAPTA concentrations to be affected. Altogether, these findings identify CBD as a dual immunomodulatory agent capable of enhancing tumor immune visibility while limiting immunotolerant HLA-G expression through receptor-specific and Ca²⁺-dependent mechanisms.